EUVIMEDOpdag EUVIMED
Randomisierte kontrollierte Studie

Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot study

Shuji Ikegami iD, Masanao Nakamura iD, Takashi Honda iD, Takeshi Yamamura, Keiko Maeda iD, Tsunaki Sawada, Eri Ishikawa, Kenta Yamamoto iD, Satoshi Furune, Takuya Ishikawa, Kazuhiro Furukawa, Eizaburo Ohno and 7 more

Alimentary Pharmacology & Therapeutics · 2023-06 · 57 (11) · 1249-1257

DOI: 10.1111/apt.17387 ↗

At a glance

Randomisierte kontrollierte Studie in Alimentary Pharmacology & Therapeutics, published online on 2023-01-16. Written by Shuji Ikegami and 18 co-authors. Institution: Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan. Major MEDLINE topics: Colitis, Ulcerative. Cited 37 times so far (Crossref); 41 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Ulcerative colitis involves an excessive immune response to intestinal bacteria. Whether administering prebiotic 1‐kestose is effective for active ulcerative colitis remains controversial.

Aims

This randomised, double‐blind, placebo‐controlled pilot trial investigated the efficacy of 1‐kestose against active ulcerative colitis.

Methods

Forty patients with mild to moderate active ulcerative colitis were randomly treated with 1‐kestose ( N = 20) or placebo (maltose, N = 20) orally for 8 weeks in addition to the standard treatment. The Lichtiger clinical activity index and Ulcerative Colitis Endoscopic Index of Severity were determined. Faecal samples were analysed to evaluate the gut microbiome and metabolites.

Results

The clinical activity index at week 8 was significantly lower in the 1‐kestose group than in the placebo group (3.8 ± 2.7 vs. 5.6 ± 2.1, p = 0.026). Clinical remission and response rates were higher in the 1‐kestose group than in the placebo group (remission: 55% vs. 20%, p = 0.048; response: 60% vs. 25%, p = 0.054). The Ulcerative Colitis Endoscopic Index of Severity at week 8 was not significantly different (2.8 ± 1.6 vs. 3.5 ± 1.6, p = 0.145). Faecal analysis showed significantly reduced alpha‐diversity in the 1‐kestose group, with a decreased relative abundance of several bacteria, including Ruminococcus gnavus group . The short‐chain fatty acid levels were not significantly different between the groups. The incidence of adverse events was comparable between the groups.

Discussion

Oral 1‐kestose is well tolerated and provides clinical improvement for patients with mild to moderate ulcerative colitis through modulation of the gut microbiome.

Subjects

MeSH terms (MEDLINE)

Colitis, UlcerativeHumansAnti-Inflammatory Agents, Non-SteroidalPilot ProjectsDouble-Blind MethodDietary SupplementsTreatment OutcomeRemission InductionTrisaccharides

Author keywords

1-kestoseprebioticsulcerative colitis

Substances

Anti-Inflammatory Agents, Non-Steroidal1-kestoseTrisaccharides

Authors and institutions

  • Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Endoscopy, Nagoya University Graduate School of Medicine, Nagoya, Japan.
  • Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.
  • B Food Science Co., Ltd., Chita, Aichi, Japan.
  • Department of Food and Nutritional Sciences, College of Bioscience and Biotechnology, Chubu University, Kasugai, Japan.
  • Department of Liver, Biliary Tract, and Pancreas Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

ORCID profiles: Shuji Ikegami, Masanao Nakamura, Takashi Honda, Keiko Maeda, Kenta Yamamoto, Hiroki Kawashima

Cite

APA

Ikegami, S., Nakamura, M., Honda, T., Yamamura, T., Maeda, K., Sawada, T., Ishikawa, E., Yamamoto, K., Furune, S., Ishikawa, T., Furukawa, K., Ohno, E., Ishigami, M., Kinoshita, F., Kadota, Y., Tochio, T., Shimomura, Y., Hirooka, Y., & Kawashima, H. (2023). Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot study. Alimentary Pharmacology & Therapeutics, 57(11), 1249-1257. https://doi.org/10.1111/apt.17387

Vancouver

Ikegami S, Nakamura M, Honda T, Yamamura T, Maeda K, Sawada T, et al. Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot study. Alimentary Pharmacology & Therapeutics. 2023;57(11):1249-1257. doi:10.1111/apt.17387

BibTeX
@article{Ikegami2023,
  author = {Ikegami, Shuji and Nakamura, Masanao and Honda, Takashi and Yamamura, Takeshi and Maeda, Keiko and Sawada, Tsunaki and Ishikawa, Eri and Yamamoto, Kenta and Furune, Satoshi and Ishikawa, Takuya and Furukawa, Kazuhiro and Ohno, Eizaburo and Ishigami, Masatoshi and Kinoshita, Fumie and Kadota, Yoshihiro and Tochio, Takumi and Shimomura, Yoshiharu and Hirooka, Yoshiki and Kawashima, Hiroki},
  title = {Efficacy of 1‐kestose supplementation in patients with mild to moderate ulcerative colitis: A randomised, double‐blind, placebo‐controlled pilot study},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2023},
  volume = {57},
  number = {11},
  pages = {1249--1257},
  doi = {10.1111/apt.17387}
}
Start for free →